Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Unoprostone - R-Tech Ueno Ltd

Drug Profile

Unoprostone - R-Tech Ueno Ltd

Alternative Names: Isopropyl unoprostone; Ocuseva; Rescula; UF-021; Unoprostone isopropyl 0.12%

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator R-Tech Ueno Ltd
  • Developer R-Tech Ueno Ltd; Santen Pharmaceutical; Sucampo Pharmaceuticals
  • Class Antiglaucomas; Antihypertensives; Eye disorder therapies; Prostaglandins; Small molecules; Vasodilators
  • Mechanism of Action Nitric oxide stimulants; Potassium channel agonists; Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension
  • Phase III Retinitis pigmentosa
  • No development reported Age-related macular degeneration
  • Discontinued Retinal detachment

Most Recent Events

  • 01 Feb 2023 Discontinued - Preclinical for Age-related macular degeneration in Japan (Topical)
  • 19 Feb 2021 Discontinued - Phase-I/II for Retinal detachment (Treatment-experienced) in Japan (Topical) (Mallinckrodt Pharmaceuticals pipeline, February 2021)
  • 28 May 2018 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in Japan (Ophthalmic, Drops)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top